{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:50:26Z","timestamp":1761663026603,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1164,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000902","name":"Pediatric Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.bbmt.2011.11.007","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T00:40:24Z","timestamp":1320885624000},"page":"324-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu\/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen"],"prefix":"10.1016","volume":"18","author":[{"given":"Prakash","family":"Satwani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"James H.","family":"Garvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filemon","family":"Dela Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Le Gall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhezhen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmella","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ria","family":"Hawks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee Ann","family":"Baxter-Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.11.007_bib1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00043426-199505000-00002","article-title":"Epidemiology of childhood acute myelogenous leukemia","volume":"17","author":"Bhatia","year":"1995","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib2","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2001.19.10.2705","article-title":"Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93","volume":"19","author":"Creutzig","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2141.1998.00677.x","article-title":"Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council\u2019s 10th AML trial. MRC Childhood Leukaemia Working Party","volume":"101","author":"Stevens","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V97.1.56","article-title":"A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission","volume":"97","author":"Woods","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib5","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1200\/JCO.2008.16.4442","article-title":"Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy","volume":"26","author":"Bunin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","article-title":"Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM)","volume":"26","author":"Michallet","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib7","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib8","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2011.11.007_bib9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2011.11.007_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bbmt.2009.10.007","article-title":"An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients","volume":"16","author":"Bhatia","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbmt.2003.11.005","article-title":"A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients","volume":"10","author":"Osunkwo","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2011.11.007_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1705785","article-title":"Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases","volume":"40","author":"Bradley","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pbc.21239","article-title":"Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation","volume":"50","author":"Roman","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2011.11.007_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/pbc.21043","article-title":"A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients","volume":"49","author":"Shereck","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2011.11.007_bib16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1399-3046.2008.01000.x","article-title":"Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning","volume":"13","author":"Waxman","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non parametric estimation for incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2011.11.007_bib18","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-08-0894","article-title":"Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia","volume":"14","author":"Bornhauser","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2011.11.007_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.leu.2405014","article-title":"Phase I\/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome","volume":"22","author":"de Lima","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.11.007_bib20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","article-title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","volume":"148","author":"Zwaan","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib22","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2007.13.0096","article-title":"Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"26","author":"Aplenc","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.2008.07370.x","article-title":"Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia","volume":"143","author":"Brethon","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib24","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bmt.1702854","article-title":"Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin","volume":"27","author":"Simon","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib26","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2010-01-261800","article-title":"A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia","volume":"116","author":"Niewerth","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2006.10.024","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review","volume":"13","author":"Oliansky","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.bmt.1705961","article-title":"Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin","volume":"41","author":"Shenoy","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbmt.2005.05.003","article-title":"Busulfan\/melphalan\/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience","volume":"11","author":"Wall","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.007_bib30","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1182\/blood-2003-04-1288","article-title":"Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis","volume":"102","author":"Michel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib31","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"Petersdorf","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V116.21.1071.1071","article-title":"Severe toxicities during pediatric acute myeloid leukemia chemotherapy: a report from the Children\u2019s Oncology Group","volume":"116","author":"Sung","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2141.2009.07917.x","article-title":"Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group","volume":"148","author":"Litzow","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib35","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"Lowenberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib36","doi-asserted-by":"crossref","first-page":"7164s","DOI":"10.1158\/1078-0432.CCR-1004-0018","article-title":"Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia","volume":"11","author":"Roman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2011.11.007_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.exphem.2009.03.002","article-title":"Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML","volume":"37","author":"Haag","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/leu.2008.185","article-title":"Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study","volume":"23","author":"Lamba","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.11.007_bib39","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.007_bib40","first-page":"1626","article-title":"Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia","volume":"8","author":"Wells","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.11.007_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/mpo.2950220406","article-title":"Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1","volume":"22","author":"Wells","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2141.2009.07770.x","article-title":"High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival","volume":"146","author":"Jacobsohn","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.11.007_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111004769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111004769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:42:58Z","timestamp":1761057778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111004769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1083879111004769"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.11.007","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu\/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}